Handelsavisen
prelaunch
Companies Healthcare PIHLIS.HE
PI
PIHLIS.HE Nasdaq Helsinki Healthcare Facilities & Services

Pihlajalinna Oyj

€10,20
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
4,73 %
Op margin
8,0 %
ROE
19,7 %
Net margin
5,8 %
Debt / equity
1,59
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

PIHLIS.HE operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services.

Business. PIHLIS.HE is a healthcare company operating within the Healthcare Facilities & Services industry, with a primary focus on biotechnology activities. The firm generates revenue through service-based models and is headquartered in Finland. It is primarily listed on the Nasdaq Helsinki exchange under the ticker symbol PIHLIS.HE. Specific details regarding operating segments and geographic breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
BUY5 analysts
4 buy1 hold0 sell
Avg 12m price target13,03

Analyst recommendations

5 analysts · consensus Buy
Buy4
Hold1
Sell0
12-month price target
13,03
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
5 analysts · indicative
Ownership
not yet wired
Profitability
19,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PIHLIS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PIHLIS.HE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    PIHLIS.HE is a healthcare company operating within the Healthcare Facilities & Services industry, with a primary focus on biotechnology activities. The firm generates revenue through service-based models and is headquartered in Finland. It is primarily listed on the Nasdaq Helsinki exchange under the ticker symbol PIHLIS.HE. Specific details regarding operating segments and geographic breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    PIHLIS.HE has a liquidity ratio of 0.73, indicating that its current assets are less than its current liabilities, which suggests a potential liquidity risk. The company's debt-to-equity ratio is 1.59, showing that it is financed more by debt than equity, which could increase its financial risk. The company's free cash flow is 66,979,000 EUR, which is a positive sign for its ability to fund operations and growth without external financing.

    In terms of profitability, PIHLIS.HE has a return on equity of 19.72%, which is a strong indicator of its ability to generate profits from shareholders' equity. The return on assets of 6.28% suggests that the company is generating a moderate return on its total assets. These metrics are in line with the industry's preferred metrics for evaluating profitability and returns.

    PIHLIS.HE's revenue is concentrated in a single segment, as disclosed in its financial statements, with no specific geographic breakdown provided. This lack of diversification could pose a risk if the company's primary market experiences a downturn. The company's exposure to a single segment may also limit its growth potential in other areas.

    The company's growth trajectory is positive, with a strong operating income of 52,120,000 EUR and a net income of 37,587,000 EUR. Analysts have provided a mean price target of 13.03 EUR, indicating a positive outlook for the company's stock. The mean recommendation of 1.80 suggests that analysts are generally optimistic about the company's future performance.

    PIHLIS.HE faces a medium liquidity risk, as indicated by its current ratio of 0.73. The company's dilution risk is low, with no significant dilution potential reported. The company's capital structure, with a high debt-to-equity ratio, may also contribute to its financial risk. The company's free cash flow is a positive indicator, but it must be managed carefully to ensure long-term sustainability.

    Recent events, such as analyst estimates and price targets, suggest a positive outlook for PIHLIS.HE. The company has received a mix of strong-buy, buy, and hold recommendations from analysts, indicating a generally positive sentiment. The company's financial performance and market position are likely to be influenced by these analyst sentiments.

    Key takeaways
    • PIHLIS.HE has a strong return on equity of 19.72%, indicating efficient use of shareholders' equity.
    • The company's liquidity ratio of 0.73 suggests a potential liquidity risk.
    • PIHLIS.HE's debt-to-equity ratio of 1.59 indicates a higher reliance on debt financing.
    • Analysts have provided a positive outlook, with a mean price target of 13.03 EUR.
    • The company's revenue is concentrated in a single segment, which could pose a risk if the primary market experiences a downturn.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    €10,20
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    €190.6M
    Net cash
    -€272.8M
    Current ratio
    0.7
    Debt / equity
    1.6
    ROA
    6.3%
    ROE
    19.7%
    Cash conversion
    201.0%
    CapEx / revenue
    -2.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,22
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    5
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-04 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate1,22
    Revenueno estimateno estimate576,5M EUR
    Operating incomeno estimateno estimate41,5M EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution5 analysts
    Strong buy2
    Buy2
    Hold1
    Sell0
    Strong sell0
    12-month price target€13,03 · Median €12,50
    Low €11,75High €14,40
    Operating income · consensus41,5M EUR
    EPS surprise
    +29,2 %
    reported vs consensus · beat
    Revenue surprise
    +13,1 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low€11,75
    Mean€13,03
    Median€12,50
    High€14,40
    Spot€10,20
    +27.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin8,0 %Above median
    Net Margin5,8 %Above median
    ROE19,7 %Above P75
    Capex / Rev-2,5 %Above P75
    D/E1,59Bottom quartile
    Cash Conv2,01Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • PIHLIS.HE Market data — financials · 2026-05-28
    • Pihlajalinna Oyj Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PIHLIS.HECanonical
    Nasdaq Helsinki · EUR

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage